Clinical trial
Clinical Study of Previously Untreated Patients With Malignant Melanoma
NCT00232726 · Clavis Pharma, Industry · Completed
Key facts
| NCT number | NCT00232726 |
|---|---|
| Title | Clinical Study of Previously Untreated Patients With Malignant Melanoma |
| Official title | A Non-Randomised, Multicentre, Phase II Clinical Study of CP-4055 in Chemotherapy-Naïve Patients With Metastatic Malignant Melanoma |
| Lead sponsor | Clavis Pharma, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Malignant Melanoma, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | CP-4055 (ELACYT) |
| Enrollment | 42 |
| Start date | Sep 1, 2005 |
| Completion | Jul 1, 2007 |
| First posted | Oct 5, 2005 |
| Last update posted | Jul 10, 2007 |
| Countries | Norway, Sweden, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: